Zobrazeno 1 - 10
of 23
pro vyhledávání: '"S.P. Hoo"'
Publikováno v:
Practical Laboratory Medicine, Vol 27, Iss , Pp e00257- (2021)
Introduction: We evaluated the Roche Elecsys Anti-SARS-CoV-2 and Snibe SARS-CoV-2 S-RBD IgG spike chemiluminescent immunoassays and compared them to existing Roche/Abbott nucleocapsid and Abbott IgM spike assays. Methods: We enrolled 184 SARS-CoV-2 R
Externí odkaz:
https://doaj.org/article/6c28807557734fef8e973324a6453b91
Publikováno v:
Practical Laboratory Medicine, Vol 24, Iss , Pp e00201- (2021)
Introduction: We evaluated two SARS-CoV-2 antibody point-of-care tests (POCTs) (Abbott Panbio COVID-19 IgG/IgM and Roche SARS-CoV-2 Rapid Antibody tests) and compared the results to their respective chemiluminescent immunoassays (CLIAs) (Abbott Archi
Externí odkaz:
https://doaj.org/article/054185f43aa740e68ab0b6a11a175ee6
Publikováno v:
Clinica Chimica Acta; International Journal of Clinical Chemistry
Clinica Chimica Acta
Clinica Chimica Acta
Highlights • An extensive evaluation of the Abbott SARS-CoV-2 IgG assay. • The assay shows excellent sensitivity/specificity with little cross-reactivity. • Healthy volunteers and pre-pandemic samples had similar antibody cut-off indexes. • A
Publikováno v:
The Journal of Applied Laboratory Medicine
Background Little is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on Cobas e801/e602 immunoassay anal
Publikováno v:
Practical Laboratory Medicine, Vol 24, Iss, Pp e00201-(2021)
Practical Laboratory Medicine
Practical Laboratory Medicine
Introduction We evaluated two SARS-CoV-2 antibody point-of-care tests (POCTs) (Abbott Panbio COVID-19 IgG/IgM and Roche SARS-CoV-2 Rapid Antibody tests) and compared the results to their respective chemiluminescent immunoassays (CLIAs) (Abbott Archit
IntroductionAntibodies to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can increase as soon as 10-13 days after infection. We describe our evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser.M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33081fa496a015292e9fceb4c6255d81
https://doi.org/10.1101/2020.06.28.20132498
https://doi.org/10.1101/2020.06.28.20132498
BackgroundLittle is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9884889ea184b4c15a99a71d0587a355
Publikováno v:
Practical Laboratory Medicine
Practical Laboratory Medicine, Vol 27, Iss, Pp e00257-(2021)
Practical Laboratory Medicine, Vol 27, Iss, Pp e00257-(2021)
Introduction: We evaluated the Roche Elecsys Anti-SARS-CoV-2 and Snibe SARS-CoV-2 S-RBD IgG spike chemiluminescent immunoassays and compared them to existing Roche/Abbott nucleocapsid and Abbott IgM spike assays. Methods: We enrolled 184 SARS-CoV-2 R
Publikováno v:
Journal of Virological Methods
Introduction We evaluated the Roche Elecsys IL6 assay on the Cobas immunoassay analyser. Method Serum IL6 of 144 controls were compared to 52 samples from patients with COVID-like respiratory symptoms (17 SARS-CoV-2 RT-PCR positive); 25 of these were
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.